Table 3.

Baseline patient demographics and characteristics of COVID-19 positive inpatients treated with baricitinib/remdesivir/dexamethasone who did died during hospitalization. Plus–minus( ±) values are standard deviation

		Deceased Patients (n = 6)
Age—years	Mean age (year)	84.5	SD ± 7.4
Gender—no	Male (n)	4	(66.7)
	Female (n)	2	(33.3)
Ethnicity – no. (%)	Not Hispanic, Latino/a, or Spanish origin (n)	6	(100.0)
Race – no. (%)	White (n)	5	(83.3)
	Asian (n)	0	-
	African American or Black (n)	1	(16.7)
	Multiracial (n)	0	-
	Declined (n)	0	-
Past Medical History—no. (%)	Co-existing conditions: None	0	-
	Co-existing conditions: One	0	-
	Co-existing conditions: More than 2	6	100.0
	Average BMI	24
	Obesity: BMI: > 30	1	(16.7)
	Morbid Obesity: BMI: > 40	0	-
	Obstructive Sleep apnea	1	(16.7)
	Coronary artery disease	1	(16.7)
	Hypertension	4	(66.7)
	Type 2 Diabetes Mellitus	2	(33.3)
	Hyperlipidemia	2	(33.3)
	Heart failure (HFpEF, HFrEF or unspecified)	1	(16.7)
	Chronic Kidney Disease	1	(16.7)
	Atrial Fibrillation	3	(50.0)
	History of Malignancy	1	(16.7)
	Pulmonary hypertension	2	(33.3)
	Aortic stenosis	3	(50.0)
	Osteoarthritis	1	(16.7)
	Autoimmune disease (rheumatoid arthritis, psoriatic arthritis, Sjogren's Syndrome, Raynaud's phenomena, giant cell arteritis, ulcerative colitis, pemphigus vulgaris)	3	(50.0)
	Obstructive airway disease (asthma, chronic obstructive pulmonary disease, bronchiectasis and reactive airway disease)	2	(33.3)
Average duration of symptoms prior to presentation—days		3	(52.8)
Average severity of illness at presentation	NEWS-2 score	7
	WHO Clinical Status Score	4
Bilateral Pneumonia on imaging at presentation—no. (%)		4	(66.7)

Patient race and ethnicity are self-reported by patient. Body mass index is calculated by weight (kilograms) divided by square of height (meters). Percentages may not total 100 because of rounding